Articles, App Notes, Case Studies, & White Papers

  1. Let The Future Start Today: Development Of Better LNP-Based Genetic Medicines 11/8/2022

    Discover how you can accelerate the time to patients for new vaccines and therapies with innovative, streamlined technology that is quicker and more intuitive.

  2. Nanomedicine Modalities Find Path To Clinic Through Analytics 5/16/2025

    Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.

  3. mRNA: How To Build A Custom Program Using CDMO Services 1/4/2023

    Development of RNA-based therapies sits at the cutting edge of vaccine and oncology innovation, in addition to holding promise in dozens of other therapeutic areas.

  4. Ensure High Quantity And Quality Of Isolated Bacterial Ribonucleic Acid 4/29/2022

    In this scientific brief we evaluate the performance of the Pall Nucleic acid binding (NAB) Nanosep centrifugal device for nucleic acid isolation.

  5. Leveraging Global Drug Development Programs To Ensure Trial Success 2/7/2023

    Opting to take your biotech program global can help save crucial resources, produce high-quality clinical data for your therapy, and leverage unique regional advantages like region-specific indication strategies.

  6. mRNA Product Purification Process Strategies 2/15/2023

    Impurities from IVT can induce undesired immune responses and negatively impact translation efficiency. Explore the pros and cons of each option for mRNA purification.

  7. What Are The Benefits Of A Well-Designed, Robust Preclinical Development Plan? 5/9/2023

    Discover how a well-designed and robust preclinical development plan can help identify potential safety and efficacy issues early in the drug development process, ultimately reducing the risk of failure in clinical trials.

  8. Overview Of Small Cell Lung Cancer: Global Clinical Trial Landscape 11/15/2024

    Small cell lung cancer (SCLC) is a fast-growing, aggressive lung cancer subtype. Global incidence, innovative therapies, and personalized medicine are transforming treatment outcomes and survival rates.

  9. De-Mystifying, De-Risking Process Development With A CDMO 11/27/2018

    An overview of how CDMOs can help companies get started in the world of CGT manufacturing, with considerations around timing of engagement to maximize commercial and clinical success.

  10. Aseptic Sampling Best Practices - Endotoxin Binding Affinity 7/24/2018

    This technical report describes a study to evaluate binding affinity of Control Standard Endotoxin (CSE) to different plastic sample collection containers.